SEOM Clinical Guideline of management of soft-tissue sarcoma (2020)

• A. de Juan Ferré ^[1] ; R. Álvarez Álvarez ^[2] ; A. Casado Herráez ^[3] ; J. Cruz Jurado ^[4] ; A. Estival González ^[9] ; J. Martín-Broto ^[5] ; V. Martínez Marín ^[6] ; A. Moreno Vega ^[7] ; A. Sebio García ^[8] ; C. Valverde Morales ^[10]
  1. [1] Hospital Universitario Marqués de Valdecilla

     Hospital Universitario Marqués de Valdecilla

     Santander, España

     
  2. [2] Hospital General Universitario Gregorio Marañón

     Hospital General Universitario Gregorio Marañón

     Madrid, España

     
  3. [3] Hospital Clínico San Carlos de Madrid

     Hospital Clínico San Carlos de Madrid

     Madrid, España

     
  4. [4] Hospital Universitario de Canarias

     Hospital Universitario de Canarias

     San Cristóbal de La Laguna, España

     
  5. [5] Hospital Universitario Virgen del Rocío

     Hospital Universitario Virgen del Rocío

     Sevilla, España

     
  6. [6] Hospital Universitario La Paz

     Hospital Universitario La Paz

     Madrid, España

     
  7. [7] Hospital Universitario Reina Sofia

     Hospital Universitario Reina Sofia

     Cordoba, España

     
  8. [8] Hospital de la Santa Creu i Sant Pau

     Hospital de la Santa Creu i Sant Pau

     Barcelona, España

     
  9. [9] Institut Català d’Oncologia-Badalona
  10. [10] Hospital Universitario Vall d’Hebron

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 23, Nº. 5 (May), 2021 (Ejemplar dedicado a: SEOM clinical guidelines 2020), págs. 922-930
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Soft-tissue sarcomas constitute an uncommon and heterogeneous group of tumors of mesenchymal origin. Diagnosis, treatment, and management should be performed by an expert multidisciplinary team. MRI/CT of the primary tumor and biopsy is mandatory before any treatment. Wide surgical resection with tumor-free tissue margin is the mainstay for localized disease. Radiotherapy is indicated in large, deep, high-grade tumors, or after marginal resection not suitable for re-excision. Perioperative chemotherapy should be discussed for high-risk sarcomas of the extremities and trunk-wall. In the case of oligometastatic disease, patients should be considered for local therapies. First-line treatment with anthracyclines (or in combination with ifosfamide) is the treatment of choice. Other drugs have shown activity in second-line therapy and in specific histological subtypes but options are limited and thus, a clinical trial should always be discussed.